Interventional Software for Multi-immunotherapy of Solid Tumors

This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by intra-tumor (IT) injection of multiple drugs including CTLA4, PD1, and/or PDL1 antibodies combined with drugs-eluting beads loaded with IL2, chemodrug, anti-angiogenesis drug, et. al that will be recommended by an AI-based medical software named IRSW-MIM developed by a cooperating company.

NCT Number	NCT06478108
Lead Sponsor	Second Affiliated Hospital of Guangzhou Medical University Collaborators: Immuno (Guangzhou) Biomedicine S&T Ltd
Conditions	Lung Cancer, Liver Cancer, Solid Tumor, Adult
Enrollment	60 participants
Start Date	2024-04-01
Primary Completion	2028-12-30 (estimated)
Study Completion	2033-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-06-27